0001415889-25-024192.txt : 20250910 0001415889-25-024192.hdr.sgml : 20250910 20250910193453 ACCESSION NUMBER: 0001415889-25-024192 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250910 FILED AS OF DATE: 20250910 DATE AS OF CHANGE: 20250910 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Soffer Gad CENTRAL INDEX KEY: 0001612090 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-42831 FILM NUMBER: 251306929 MAIL ADDRESS: STREET 1: C/O ATARA BIOTHERAPEUTICS, INC. STREET 2: 3260 BAYSHORE BOULEVARD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER NAME: FORMER CONFORMED NAME: Sofer Gad DATE OF NAME CHANGE: 20140627 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LB PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001691082 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 575 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 917-450-6581 MAIL ADDRESS: STREET 1: 575 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: LB PHARMACEUTICALS INC. DATE OF NAME CHANGE: 20161129 3 1 form3-09102025_110950.xml X0206 3 2025-09-10 0 0001691082 LB PHARMACEUTICALS INC LBRX 0001612090 Soffer Gad C/O LB PHARMACEUTICALS INC ONE PENNSYLVANIA PLAZA, SUITE 1025 NEW YORK NY 10119 false true false false Chief Business Officer Employee Stock Option (Right to Buy) 41.84 2035-02-10 Common Stock 26893 D One fourth (1/4) of the shares subject to the option award shall vest on February 5, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. /s/ Marc Panoff, Attorney-in-Fact 2025-09-10 EX-24 2 ex24-09102025_110951.htm ex24-09102025_110951.htm

POWER OF ATTORNEY


(For Executing Forms 3, 4, and 5)


Know all by these presents, that the undersigned hereby constitutes and appoints each of Heather Turner and Marc Panoff of LB Pharmaceuticals Inc (the "Company"), signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:


(1)

prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC") Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;


(2)

do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute such Forms 3, 4 or 5 (including amendments thereto) and timely file such forms with the SEC and any stock exchange or any similar authority; and


(3)

take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in the attorney-in-fact's discretion.


The undersigned hereby grants to each such attorneyinfact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneyinfact, or such attorneyinfact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.


This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company.  


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.



Date:  September 9, 2025



/s/ Gad Soffer

Name: Gad Soffer